Financial Data and Key Metrics Changes - For Q4 2025, revenue was $194.8 million, with Adjusted EBITDA at $65 million, leading to a full year revenue of $796.9 million, reflecting a 1% year-over-year increase [20] - Full year Adjusted EBITDA was $270.5 million, representing a 4% growth over 2024 [20] - Revenue from Pharma Direct increased to $151.4 million, up 41% year-over-year, driven by deeper sell-through at manufacturers and growth in consumer direct pricing [21] Business Line Data and Key Metrics Changes - Subscription revenue decreased by 3% year-over-year to $83.8 million, although early adoption of condition-specific subscriptions, particularly for weight loss, exceeded expectations [21] - The core marketplace remains foundational, but the company is increasingly focusing on Pharma Manufacturer Solutions as a key growth driver [9][11] Market Data and Key Metrics Changes - Monthly Active Consumers fell by 14% in 2025 compared to the previous year, but the company expects this number to stabilize from Q4 2025 through Q4 2026 [24] - The company reported nearly 25 million consumers and over 1 million healthcare professionals using its platform annually [11] Company Strategy and Development Direction - The company is evolving its business model to focus on Pharma Direct and Employer Direct offerings, which are seen as key growth opportunities [19][25] - The strategy aligns with the increasing consumer demand for direct-to-consumer healthcare solutions and the evolving dynamics of prescription access and pharmacy economics [7][25] Management's Comments on Operating Environment and Future Outlook - Management noted that affordability pressures and policy dynamics are reshaping access and pricing in healthcare, which plays to the company's strengths [7] - The company anticipates revenue pressure in 2026 due to strategic investments aimed at long-term durability, with Pharma Direct revenue expected to grow at least 30% year-over-year [23][24] Other Important Information - The company ended the year with $261.8 million in cash and approximately $80 million in unused capacity under its revolving credit facility [22] - The company repurchased approximately 48.9 million shares at an average price of $4.45 per share, totaling $217.4 million, signaling management's confidence in the company's future [22] Q&A Session Summary Question: Can you elaborate on the revenue guidance and unit economics? - Management explained that the decline in revenue is driven by the loss of significant revenue from Rite Aid and a shift of claims to Pharma Direct, which is reflected in the growth of point-of-sale programs [29][30] Question: How is the Pharma budget spending environment affecting new programs? - Management noted that spending has been pulled forward this year, with pharmaceutical manufacturers continuing to invest in direct-to-consumer programs [42][44] Question: What is the future of the legacy business amidst the focus on Pharma Direct? - Management confirmed that the core Rx Marketplace will remain foundational, but there is a strategic shift towards direct-to-consumer experiences as consumer preferences evolve [51][52] Question: How is the company addressing margin pressure? - Management indicated that while there is margin pressure, the focus is on stabilizing the underlying volume of scripts and renegotiating lower fees for long-term predictability [30][74] Question: What changes are being made to sales and marketing efforts in 2026? - Management stated that marketing spend will be redirected towards specific programs, with a focus on optimizing return on advertising spend [83][86]

Financial Data and Key Metrics Changes - For Q4 2025, revenue was $194.8 million, with Adjusted EBITDA at $65 million, leading to a full year revenue of $796.9 million, a 1% increase year-over-year [20] - Full year Adjusted EBITDA was $270.5 million, reflecting a 4% growth over 2024 [20] - Prescription transactions revenue declined by 6% year-over-year to $544 million, impacted by the Rite Aid bankruptcy and lower volume through an Integrated Savings Program partner [21] - Subscription revenue decreased by 3% year-over-year to $83.8 million, although early adoption of condition-specific subscriptions showed promise [21] - Revenue from Pharma Direct increased to $151.4 million, up 41% year-over-year, driven by deeper sell-through at manufacturers [21] Business Line Data and Key Metrics Changes - Pharma Manufacturer Solutions, now referred to as Pharma Direct, has become a key growth engine, with full year revenue up more than 40% in 2025 [9][21] - The prescription marketplace showed progress with order volume up 83% quarter-over-quarter, and direct contracts established with 9 of the top 10 retail pharmacies [15] - Condition-specific subscriptions, particularly for weight loss, have exceeded expectations, indicating strong potential for future revenue growth [16][21] Market Data and Key Metrics Changes - The healthcare landscape is shifting towards affordability and transparency, with consumers increasingly expecting direct-to-consumer access [7][10] - The growth of GLP-1 treatments for weight management has accelerated direct-to-consumer models, highlighting the need for transparent pricing and convenience [10][12] Company Strategy and Development Direction - The company is evolving its business model to focus on Pharma Manufacturer Solutions as a key growth driver, reflecting changes in prescription access and pharmacy economics [8][9] - GoodRx aims to enhance its core platform by accelerating subscriptions and deepening retail relationships, positioning itself for long-term growth despite near-term financial impacts [9][23] - The introduction of Employer Direct is seen as a natural extension of the GoodRx platform, addressing gaps in traditional insurance coverage [18][19] Management's Comments on Operating Environment and Future Outlook - Management noted that affordability pressures and policy dynamics are reshaping access and pricing in healthcare, which plays to GoodRx's strengths [7][25] - The company anticipates pressure on prescription transactions revenue in 2026 but expects Pharma Direct revenue to grow at least 30% year-over-year [23][24] - Management expressed confidence in the strategic direction and the ability to deliver value in a changing healthcare environment [25][26] Other Important Information - The company ended the year with $261.8 million in cash and approximately $80 million in unused capacity under its revolving credit facility [22] - Share repurchases totaled approximately 48.9 million shares at an average price of $4.45 per share, signaling management's confidence in the company's future [22] Q&A Session Summary Question: Can you elaborate on the revenue guidance and unit economics? - Management explained that the decline in prescription transaction revenue is due to the impact of Rite Aid's bankruptcy and a shift of claims to Pharma Direct, which is expected to stabilize over the long term [30][32] Question: How is the pharma budget spending environment affecting Pharma Direct programs? - Management noted that spending has been pulled forward this year, with pharmaceutical manufacturers continuing to invest in direct-to-consumer programs [42][44] Question: What is the future of the legacy business amidst the focus on Pharma Direct? - Management confirmed that the core Rx Marketplace will remain foundational, but there is a strategic shift towards direct-to-consumer experiences and partnerships with pharmaceutical manufacturers [51][52] Question: How is the company addressing margin pressure and price stability? - Management acknowledged that while there is margin pressure, the interrelation between Pharma Direct and the core business allows for shared brand economics, which is expected to stabilize pricing in the medium term [93]

Core Insights - Hims & Hers Health, Inc. (HIMS) operates a digital healthcare platform that integrates care delivery, data, and fulfillment into a consumer-facing ecosystem, enhancing personalization and continuity of care through proprietary technology [1][7] Group 1: Platform Development - The platform is evolving from episodic treatment to a proactive, data-driven model, with the launch of Labs for longitudinal biomarker tracking that informs provider action plans [2][7] - Investments in artificial intelligence (AI) and platform infrastructure are aimed at improving diagnostics, treatment matching, and care orchestration, positioning software and data as core differentiators [2][3] Group 2: Strategic Initiatives - The acquisition of YourBio Health introduces patented blood sampling technology, allowing for better integration of diagnostics with digital care delivery [3] - Ongoing investments in technology and AI capabilities are designed to enhance personalized care through proprietary systems and data feedback loops [3] Group 3: Market Performance - Hims & Hers shares have decreased by 44.8% over the past year, underperforming the industry decline of 35.1% [6] - The forward 12-month price-to-sales (P/S) ratio for HIMS is 1.9X, lower than the industry average of 3.7X and its three-year median of 2.6X [9] Group 4: Earnings Estimates - The Zacks Consensus Estimate for HIMS' earnings per share in 2025 suggests an 85.2% improvement from 2024 [9] - Current estimates for the upcoming quarters indicate a potential recovery, with EPS expected to rise from 0.50 in 2025 to 0.58 in 2026 [10]

Core Insights - Hims & Hers Health, Inc. operates as a connected healthcare platform, linking consumers with licensed clinicians, diagnostics, and pharmaceutical partners, focusing on coordinated care rather than isolated transactions [1][3] Company Developments - Recent launches include a new Labs offering for whole-body diagnostic testing, providing customers with biomarker insights and clinician-developed action plans [2] - The menopause specialty connects women to hormonal health providers, expanding treatment options with ongoing clinical oversight [2] - Innovative testosterone treatments for men, supported by at-home testing and provider review, illustrate the integration of pharmaceutical collaboration, diagnostics, and personalized care [2][7] Market Performance - Hims & Hers shares have gained 39.1% year to date, outperforming the industry growth of 9.4% [6] - The forward 12-month price-to-sales ratio for Hims & Hers is 2.8X, lower than the industry average of 5.1X but higher than its three-year median of 2.6X [9] Earnings Estimates - The Zacks Consensus Estimate for Hims & Hers' 2025 earnings per share suggests a 77.8% improvement from 2024 [9] - Current quarter EPS estimate is 0.04, with a projected increase to 0.14 next quarter [10]

Financial Data and Key Metrics Changes - For Q3 2025, total revenue was $196 million, an increase of approximately $1 million compared to the prior year [20] - Prescription transaction revenue decreased by 9% year-over-year, primarily due to the impact of Rite Aid store closures and lower transaction volume in the integrated savings program [21] - Adjusted EBITDA for the quarter was $66.3 million, reflecting a 2% increase year-over-year and an adjusted EBITDA margin of 33.8%, which is an improvement of 50 basis points compared to the prior year [22] Business Line Data and Key Metrics Changes - Manufacturer solutions revenue grew by 54% year-over-year to $43.4 million, driven by strong execution and expansion across new and existing brand partnerships [21][11] - The company has over 200 brand affordability programs on its platform, with nearly 80 offering cash prices [13] Market Data and Key Metrics Changes - The ongoing changes in the U.S. healthcare environment, particularly around prescription drug pricing, are seen as a significant opportunity for GoodRx, especially with the introduction of Trump Rx and the focus on price transparency [6][9] - The company is positioned to benefit from the anticipated increase in uninsured individuals and higher out-of-pocket costs due to changes in the Affordable Care Act marketplace subsidies and Medicaid support [9] Company Strategy and Development Direction - GoodRx is focused on expanding partnerships with pharmaceutical manufacturers and retail pharmacies to enhance access and affordability for consumers [19] - The company is investing in its manufacturer solutions capabilities and aims to deliver a true end-to-end e-commerce model to the pharmaceutical industry [14] - The new brand campaign, "The Savings Wrangler," aims to reinforce GoodRx's position as a trusted name in prescription savings and has already shown positive results in key marketing metrics [18] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the broader healthcare environment's challenges but remains confident in GoodRx's ability to navigate these changes and capitalize on emerging opportunities [10][25] - The company expects continued growth in its manufacturer solutions segment, projecting approximately 35% revenue growth in 2025 [24] - Management is optimistic about the long-term growth potential as the market shifts towards greater price transparency and consumer-direct models [9][26] Other Important Information - The company repurchased approximately 13.4 million shares at an average price of $4.61 per share, totaling $61.6 million, with about $81.4 million remaining under its share repurchase program [22] - GoodRx is actively engaged with the administration and HHS to inform policy efforts that expand access and affordability for all Americans [6] Q&A Session Summary Question: Can you discuss the stabilizing PTR environment and its implications for GoodRx? - Management noted that 2025 has been challenging due to various macro conditions but anticipates a return to growth in 2026 as more people may become uninsured, creating a tailwind for GoodRx [30][31] Question: How does GoodRx differentiate itself in the manufacturer solutions space? - GoodRx highlighted its position as the number one digital prescription marketplace, providing manufacturers with significant ROI and access to a large consumer base [33] Question: What are the implications of PBMs moving towards point-of-sale discounts? - Management expressed support for this shift, indicating that it aligns with GoodRx's mission of enhancing affordability for consumers at the pharmacy counter [36][37] Question: How will GoodRx integrate with Trump Rx? - GoodRx is actively working with HHS to integrate its pricing into the Trump Rx platform, positioning itself as a key provider of pricing information [39][41] Question: What is the outlook for the ISP relationship and potential new products? - Management indicated that while the ISP relationship has evolved, there remains potential for new product offerings that could enhance affordability for consumers [43][44]

Core Insights - GoodRx has experienced significant stock volatility, with a 52-week high of $7.11 and a current valuation approximately 49% below its YTD high of $5.81, despite an 18% increase from its YTD low of $3.31 [1] - The company is valued at around $1.4 billion and serves nearly 30 million users annually, saving over $85 billion in medication costs [2] - GoodRx's mission is to address high prescription drug prices, providing tools for price comparison and discounts, and has expanded its services to include telehealth and pet healthcare solutions [3] Stock Performance - GDRX stock has seen fluctuations, with a notable increase of over 5% following news of potential collaboration with the Trump administration on the TrumpRx initiative [5][9] - The stock is currently trading at 18.9 times forward earnings and 1.68 times sales, indicating it is undervalued compared to sector averages [10] Financial Performance - In Q2, GoodRx reported a modest revenue increase of 1% year-over-year to $203.1 million, with prescription transactions down 3% to $143.1 million [11][12] - Subscription revenue decreased by 7% to $20.5 million, while revenue from pharma manufacturer solutions surged by 32% to $35 million [13] - Adjusted EPS rose slightly to $0.09, and adjusted EBITDA increased to $69.4 million, reflecting improved cash flow management with $49.6 million generated from operations [14] Future Outlook - GoodRx anticipates revenue growth in 2025 despite short-term challenges, projecting adjusted EBITDA between $265 million and $275 million [16] - Analysts expect fiscal 2025 earnings to increase by 54% year-over-year to $0.20 per share, with further growth projected for 2026 [17] Strategic Developments - The potential partnership with the TrumpRx initiative could enhance GoodRx's role in digital healthcare, allowing it to integrate its services into a government-backed platform [20][21] - Analysts have mixed views on the impact of TrumpRx, with some seeing it as an opportunity for growth while others express concerns about potential disruptions to GoodRx's traditional business model [22][23] Analyst Ratings - GoodRx has a "Moderate Buy" rating overall, with an average price target of $5.46, suggesting a potential upside of 40% [24]